Venmax Drugs and Pharmaceuticals Ltd
Approval of Modification of draft Scheme of Amalgamation submitted on November 12, 2025 between Hatri Pharma Private Limited (Transferor Company) and Venmax Drugs and Pharmaceuticals Limited ....
M&A
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 27 Mar 2026, 04:08 PM IST · BSE ID: 3a61ba1b-5761-425b-92af-a576b55f61d5
View Original BSE Filing (PDF)
💡
In Simple Terms
Venmax Drugs' board approved changes to the share structure in its planned merger with Hatri Pharma, increasing issued shares and reflecting completed warrant conversions.
🤖 AI Summary
- Board approves modification to draft scheme of amalgamation between Hatri Pharma and Venmax Drugs dated March 27, 2026
- Issued and paid-up capital increased to 1,15,82,930 equity shares worth Rs. 11,58,29,300 from prior 80,07,930 shares
- Convertible warrant allotments reduced to 36,81,000 pending warrants after 63,44,000 shares converted from warrant exercises
- Modified scheme incorporates updated share capital structure in Para 2.2 of Share Capital Clause for transferee company
🔢 Key Numbers — exact figures from BSE filing, not rounded
Issued, Subscribed & Paid-up Capital (Amended)
Rs. 11,58,29,300 (1,15,82,930 equity shares of Rs. 10 each)
Issued, Subscribed & Paid-up Capital (Previous)
Rs. 8,00,79,300 (80,07,930 equity shares of Rs. 10 each)
Convertible Warrant Allotments Pending
36,81,000 equity share warrants of Rs. 5 each (Rs. 1,84,05,000)
Warrant Conversions Completed
63,44,000 equity shares converted from 1,00,25,000 original warrant issuance
Authorized Share Capital
Rs. 22,00,00,000 (2,20,00,000 equity shares of Rs. 10 each)
🏢 How This Affects the Company
The amalgamation, once shareholder and regulatory approval is secured, will consolidate Hatri Pharma's operations into Venmax Drugs, expanding the combined entity's pharmaceutical portfolio and market presence.
The increase in issued and paid-up capital from Rs. 8,00,79,300 to Rs. 11,58,29,300 reflects equity issued for merger consideration and warrant conversions. The reduction in pending warrant allotments from 72,56,400 to 36,81,000 confirms 63,44,000 warrant conversions completed, strengthening the equity base.
Post-completion, Hatri Pharma's operations will be integrated into Venmax Drugs as the surviving legal entity. The modified share structure will govern post-merger voting rights and shareholding patterns.
The merger remains subject to shareholder approval and regulatory clearances. Pending warrant allotments (36,81,000 shares) create future dilution. Integration execution risks and regulatory approval timelines remain.
👥 What This Means For Shareholders
✅
Action Required
Monitor upcoming shareholder approval notice for the amalgamation scheme and track regulatory clearance progress through BSE filings.
👤
Who Is Affected
All equity shareholders will experience dilution from pending warrant conversions (36,81,000 shares) upon final allotment. Voting rights and shareholding percentages will change post-merger completion.
🔍
Management Signal
Progressive warrant conversion execution and formal scheme modification filing indicate management commitment to completing the amalgamation within regulatory framework.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Shareholder approval notice — watch for EGM or postal ballot announcement for amalgamation scheme ratification
Regulatory clearance timeline — track NCLT approval or other required approvals filed as Reg 30 intimations
Remaining warrant allotments — monitor completion of 36,81,000 pending share warrant conversions in quarterly disclosures
MEDIUM RISK
Merger completion contingent on shareholder and regulatory approvals. Pending warrant dilution (36,81,000 shares) and integration execution risks present.
💡 Investor Takeaway
Board approved updated share capital structure for Hatri Pharma merger: issued capital rises to Rs. 11,58,29,300 (1,15,82,930 shares), with 36,81,000 warrant allotments pending. Merger completion requires shareholder and regulatory approvals; timeline uncertain.
⚖️ Strengths & Concerns
✅ Positives
- Warrant conversion progress evident: 63,44,000 shares converted, reducing future dilution burden and strengthening equity base
- Clear capital structure amendment filed formally, demonstrating compliance with SEBI Regulation 30 disclosure requirements
⚠️ Concerns
- Significant pending warrant allotments of 36,81,000 equity shares remain outstanding, creating future dilution exposure
- Merger approval status unclear: filing shows board approval only; shareholder vote and regulatory clearance still pending
📅 Company Track Record
First BSE filing identified for this company in current data set. Venmax Drugs incorporated 1988 (CIN: 124230TG1988P1C009102). Prior warrant issuance of 1,00,25,000 shares at Rs. 20 per warrant shows previous capital raises; 63,44,000 already converted.
Based on publicly available historical data. For context only.